Summary
Quest Diagnostics Incorporated's 2009 Form 10-K highlights a company firmly established as the world leader in diagnostic testing, information, and services. For the fiscal year ended December 31, 2009, the company reported net revenues of $7.5 billion, processing approximately 148 million test requisitions. Quest Diagnostics' strategy focuses on delivering a superior patient experience, driving quality through Six Sigma, leveraging its extensive assets, and leading in medical innovation and IT solutions. The company detailed its growth in specialized testing areas like gene-based and esoteric testing, and anatomic pathology, noting significant strength in cancer diagnostics following the acquisition of AmeriPath. Financially, the company demonstrated resilience, with income from continuing operations growing to $730 million, or $3.88 per diluted share, up from $632 million, or $3.22 per diluted share, in 2008. This growth was supported by improved operating performance, lower interest expenses, and actions to enhance operational efficiency. The company also continued its commitment to shareholder returns through dividends and share repurchases. Despite economic challenges, Quest Diagnostics maintained a strong market position, driven by its comprehensive test menu, extensive network, and commitment to innovation and quality.
Financial Highlights
56 data points| Revenue | $7.46B |
| Cost of Revenue | $4.32B |
| Gross Profit | $3.13B |
| SG&A Expenses | $1.75B |
| Operating Expenses | $6.10B |
| Operating Income | $1.36B |
| Interest Expense | $146.59M |
| Net Income | $729.11M |
| EPS (Basic) | $3.91 |
| EPS (Diluted) | $3.87 |
| Shares Outstanding (Basic) | 185.95M |
| Shares Outstanding (Diluted) | 187.80M |
Key Highlights
- 1Quest Diagnostics processed approximately 148 million test requisitions in 2009, generating $7.5 billion in net revenues.
- 2The company reported income from continuing operations of $730 million ($3.88 per diluted share) in 2009, an increase from $632 million ($3.22 per diluted share) in 2008.
- 3Key strategic priorities include enhancing the patient experience, maintaining Six Sigma quality, leveraging assets, and driving innovation in medical and IT solutions.
- 4Quest Diagnostics is a leader in specialized testing areas such as gene-based, esoteric, and anatomic pathology testing, particularly in cancer diagnostics.
- 5The company actively pursued debt reduction and share repurchases, demonstrating a commitment to financial flexibility and shareholder value.
- 6Quest Diagnostics continued to invest in healthcare information technology, aiming to improve patient care and streamline workflows through solutions like the Care360 suite.
- 7Despite a challenging economic environment, the company's financial performance showed improvement, driven by revenue growth and cost-efficiency initiatives.